LETTER TO THE EDITOR |
Nirmala Agarwal, FRCOG
Department of Gynecology and Obstetrics,
Sant Parmanand Hospital,
Delhi 110054, India
To the Editor.—
Prestabilization of ProQuad by the addition of
2.5 mg of a urea-based stabilizer in each dose1 would be of maximal utility in pediatric practice in the United States and elsewhere through future ProQuad accelerated stabilization toward exposure to ambient room temperatures. With impending global climate change, live vaccine formulations (both solitary and multiple) would encounter an inimical environment. Vaccine aliquots offered in pediatric practice or public health centers in remote locations should be fully potent and immunogenic. ProQuad and other combination vaccines that incorporate stabilizers should be programmed to address catastrophes and disasters. During August 2005, the aftereffects of Hurricane Katrina were associated with prolonged power shutdowns, and the auxiliary generators in hospitals and laboratories ran out of fuel.2
FOOTNOTES
Statements appearing here are those of the writers and do not represent the offcial position of the American Academy of Pediatrics or its Committees. Comments on any topic, including the contents of PEDIATRICS, are invited from all members of the profession; those accepted for publication will not be subject to major editorial revision but generally must be no more than 400 words in length. The editors reserve the right to publish replies and may solicit responses from authors and others.
Please see www.pediatrics.org for instructions on submitting letters.
REFERENCES
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||